Skip to content
MarketScale
‹ Back to IndustriesSciences

What Updated Annex 1 Regulations Mean for Sterile Manufacturing Companies in 2023

Over the summer new GMP Annex 1 regulations were released by the FDA and EMA, prompting new changes to become standard protocolin sterile manufacturing companies. By August 2023, the regulations will take effect and companies will have to ensure that they are in compliance with the guidelines set. Discussing this on a new podcast, host…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Benchmark Products on MarketScale.

By Healthcare · Annex 1Benchmark ProductsCompaniesDisinfecting
Share

Key takeaways

01

Over the summer new GMP Annex 1 regulations were released by the FDA and EMA, prompting new changes to become standard protocolin sterile manufacturing companies.

02

By August 2023, the regulations will take effect and companies will have to ensure that they are in compliance with the guidelines set.

03

Discussing this on a new podcast, host…

Over the summer new GMP Annex 1 regulations were released by the FDA and EMA, prompting new changes to become standard protocolin sterile manufacturing companies. By August 2023, the regulations will take effect and companies will have to ensure that they are in compliance with the guidelines set. Discussing this on a new podcast, host Gabrielle Bejarano talked to Chris White, who is the Global Head of GMP at Adamas Consulting, about what’s new and different, and how manufacturing companies and facilities can meet the regulations of Annex 1.

Of the standout changes, White noted that Annex 1 makes a big distinction between what cleaning is versus what disinfection is, citing that the regulations detail specific differences, and specify that disinfection can only occur after cleaningis complete. Annex 1 emphasizes that there is an “acknowledging that surfaces can only be adequately disinfected once they’re clean —so you have the separation of cleaning versus disinfection,” said White.

He also added that there is a significant emphasis on “material transfer”,which according to White, is “monitoring the materials throughout your facility,and as they are transferred into your more critical areas, how to mitigate the impact of the risk of contamination during that process.”

Evidently, the updated Annex 1 regulations are placing a focus on higher scrutiny in the quality production of sterile manufacturing healthcare products.

A solution to avoiding contamination is the Benchmark Products Suite° line —a series of Ultra-Fiber material products-to help eliminate residue. Leftover residue is quite common in sterile manufacturing companies, and White said that the sources are normally the same culprits, which are disinfectants themselves, sporicidal agents, and even lubricants from equipment.Residues that are not removed can potentially harbor dormant bio burden and impact the effectiveness of disinfectants subsequently applied.

In terms of validating newly established SOPs that comply with Annex 1, Chris suggests choosing a time of facility shut down in an uncleaned area and conducting baseline environmental monitoring sampling. Following a cleaning according to the new SOP, sampling in the same locations is repeated to show an overall reduction in the level of bio burden.

He mentioned that the Benchmark Products Suite line offers“Ultra Fiber technology, which allows you to remove residues to make better surface contact with the surfaces that you’re trying to disinfect, and it also contains the contamination without transferring it from one surface to another.”

Companies that prioritize the cleaning steps and create a dedicated schedule for it will be on track to meet the compliance goals.

Benchmark Products

Part of this channel

Benchmark Products

ISO-certified cleanroom supplies for life science manufacturers.

Visit the channel →

About the author

H
Healthcare

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

H
Healthcare